lidocaine topical spray 5% solution (APC101) / Andros Pharma - LARVOL DELTA

A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients with Postherpetic Neuralgia. (ANZCTR) - P2/3 | N=333 | Not yet recruiting | Sponsor: Andros Pharmaceuticals Pty Ltd

New P2/3 trial • Neuralgia • Pain

Jingtian’s APC101 for relieving post-herpetic neuralgia applies for phase II clinical trials, making it the first Pindang topical product [Google translation] (stock.yahoo) - "Jingtian Technology...announced on the 18th that APC101 spray, a new drug under development for the relief of post-herpetic neuralgia, has been An application for phase II clinical trial review of postherpetic neuralgia in the head and neck area was submitted to the Food and Drug Administration of the Ministry of Health and Welfare of Taiwan, and 21 cases are expected to be accepted....This trial is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of APC101 in patients with postherpetic neuralgia of the head and neck. 21 subjects are expected to be included."

New P2 trial • CNS Disorders • Neuralgia • Pain